Drugs / Lu AG06466
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT05219838 | Jan → Aug 2022 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05201092 | Jan → Feb 2022 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05177029 | Nov → Dec 2021 | — | H. Lundbeck A/S | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05081518 | Sep 2021 → Apr 2022 | focal epilepsy | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 1 | NCT04990219 | Sep 2021 → Jan 2023 | multiple sclerosis | H. Lundbeck A/S | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05028673 | Aug → Dec 2021 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04974359 | Jun 2021 → Jan 2022 | fibromyalgia | H. Lundbeck A/S | Terminated | No outcome recorded |
| Phase 1 | NCT04713254 | Dec 2020 → Apr 2021 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04597450 | Sep 2020 → Feb 2023 | post-traumatic stress disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04419636 | May 2020 → Feb 2021 | — | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04405323 | May → Jul 2020 | — | H. Lundbeck A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu AG06466 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04597450 ↗ |
| Action | Inhibit | “the binding will result in inhibition of an enzyme in the endocannabinoid system called monoacylglycerol lipase (MAGL)” NCT05219838 ↗ |
| Route | Oral | “hard capsules, orally, single doses” NCT04405323 ↗ |